Compass Therapeutics, Inc. (NASDAQ:CMPX)
| Market Cap | $123.94M-86.1% |
| Revenue (ttm) | $0 |
| Net Income | -$86.36M-31.2% |
| EPS | -$0.46+1.1% |
| Shares Out | 180.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,823,573 |
| Open | $0.68 |
| Previous Close | $0.68 |
| Day's Range | $0.64 - $0.73 |
| 52-Week Range | $0.57 - $6.88 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | $4.67(+578.58%) |
| Earnings Date | Mar 4, 2027 |
About CMPX
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Compass Therapeutics, Inc. Stock Analysis — InsiderScore
Compass Therapeutics, Inc. scored higher than 70% of companies evaluated by InsiderBuying, and ranked 27th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Compass Therapeutics, Inc. bought $27.1K of stock across 3 purchases in the last 90 days, the largest of them $18.4K.
The average purchase added about 3% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
5 firms rating CMPX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 4, 2027Earnings report
$CMPX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CMPX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CMPX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CMPX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CMPX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CMPX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CMPX
| XBIState Street SPDR S&P Biotech ETF | $3.34M |
| VTIVanguard Morningstar Total Stock Market ETF | $2.60M |
| IWMiShares Russell 2000 ETF | $2.37M |
| VXFVanguard Extended Market ETF | $1.31M |
| FESMFidelity Enhanced Small Cap ETF | $1.17M |
| IWNiShares Russell 2000 Value ETF | $822.17K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CMPX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+34.7 since Sep 26Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.30% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.10% |
| XBI | State Street SPDR S&P Biotech ETF | 0.04% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.02% |
| PWS | Pacer WealthShield ETF | 0.01% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.01% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.00% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
